Construct: ORF ccsbBroadEn_02634
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF004299.1_s300c1, BRDN0000388236
- DNA Barcode:
- None
- Epitope Tag:
- None
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- RABL2B (11158)
Vector Information:
- Vector Backbone:
- pDONR223
- Pol II Cassette 1:
- n/a
- Pol II Cassette 2:
- n/a
- Selection Marker:
- n/a
- Visible Reporter:
- n/a
- Epitope Tag:
- n/a
Current transcripts matched by this ORF:
Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
---|---|---|---|---|---|---|---|---|
1 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001003789.3 | 100% | 100% | |
2 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130919.3 | 100% | 100% | |
3 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130920.3 | 100% | 100% | |
4 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130921.3 | 100% | 100% | |
5 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350003.2 | 100% | 100% | |
6 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350004.2 | 100% | 100% | |
7 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028552.1 | 100% | 100% | |
8 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028555.1 | 100% | 100% | |
9 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_024452147.1 | 100% | 100% | |
10 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130922.3 | 99.5% | 99.5% | 408_409insGCA |
11 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350005.2 | 99.5% | 99.5% | 408_409insGCA |
12 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350006.2 | 99.5% | 99.5% | 408_409insGCA |
13 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350007.2 | 99.5% | 99.5% | 408_409insGCA |
14 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_007081.4 | 99.5% | 99.5% | 408_409insGCA |
15 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028556.1 | 99.5% | 99.5% | 408_409insGCA |
16 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306158.2 | 99.2% | 98.6% | (many diffs) |
17 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306159.2 | 99.2% | 98.6% | (many diffs) |
18 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354412.2 | 99.2% | 98.6% | (many diffs) |
19 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354413.2 | 99.2% | 98.6% | (many diffs) |
20 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354414.2 | 99.2% | 98.6% | (many diffs) |
21 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003213.1 | 99.2% | 98.6% | (many diffs) |
22 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003214.1 | 99.2% | 98.6% | (many diffs) |
23 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003215.1 | 99.2% | 98.6% | (many diffs) |
24 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003216.1 | 99.2% | 98.6% | (many diffs) |
25 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452575.1 | 99.2% | 98.6% | (many diffs) |
26 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354416.2 | 98.8% | 98.2% | (many diffs) |
27 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_007082.5 | 98.8% | 98.2% | (many diffs) |
28 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_013412.4 | 98.8% | 98.2% | (many diffs) |
29 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003220.1 | 98.8% | 98.2% | (many diffs) |
30 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003222.1 | 98.8% | 98.2% | (many diffs) |
31 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350016.2 | 97.4% | 97.4% | 506_523del |
32 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350017.2 | 97.4% | 97.4% | 506_523del |
33 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028551.1 | 97% | 97% | 408_409insGCA;503_520del |
34 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354417.2 | 96.9% | 96.5% | (many diffs) |
35 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003210.1 | 96.7% | 96.1% | (many diffs) |
36 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003211.1 | 96.7% | 96.1% | (many diffs) |
37 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003212.1 | 96.3% | 95.7% | (many diffs) |
38 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350008.2 | 95.8% | 95.8% | 505_534del |
39 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350009.2 | 95.8% | 95.8% | 505_534del |
40 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350010.2 | 95.8% | 95.8% | 505_534del |
41 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350011.2 | 95.8% | 95.8% | 505_534del |
42 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350012.2 | 95.8% | 95.8% | 505_534del |
43 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028543.1 | 95.8% | 95.8% | 505_534del |
44 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028544.1 | 95.8% | 95.8% | 505_534del |
45 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028546.1 | 95.8% | 95.8% | 505_534del |
46 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130923.3 | 95.3% | 95.3% | 408_409insGCA;502_531del |
47 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350013.2 | 95.3% | 95.3% | 408_409insGCA;502_531del |
48 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350014.2 | 95.3% | 95.3% | 408_409insGCA;502_531del |
49 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350015.2 | 95.3% | 95.3% | 408_409insGCA;502_531del |
50 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028547.1 | 95.3% | 95.3% | 408_409insGCA;502_531del |
51 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354405.2 | 95.1% | 94.5% | (many diffs) |
52 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354406.2 | 95.1% | 94.5% | (many diffs) |
53 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354407.2 | 95.1% | 94.5% | (many diffs) |
54 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354408.2 | 95.1% | 94.5% | (many diffs) |
55 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354409.2 | 95.1% | 94.5% | (many diffs) |
56 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712208.3 | 95.1% | 94.5% | (many diffs) |
57 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712209.3 | 95.1% | 94.5% | (many diffs) |
58 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_011510509.2 | 95.1% | 94.5% | (many diffs) |
59 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003203.1 | 95.1% | 94.5% | (many diffs) |
60 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003204.1 | 95.1% | 94.5% | (many diffs) |
61 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003205.1 | 95.1% | 94.5% | (many diffs) |
62 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003207.1 | 95.1% | 94.5% | (many diffs) |
63 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306160.3 | 94.7% | 94.1% | (many diffs) |
64 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354410.2 | 94.7% | 94.1% | (many diffs) |
65 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452573.1 | 94.7% | 94.1% | (many diffs) |
66 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306161.2 | 71.6% | 71.1% | (many diffs) |
67 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354421.2 | 71.6% | 71.1% | (many diffs) |
68 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354423.2 | 71.6% | 71.1% | (many diffs) |
69 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003226.1 | 71.6% | 71.1% | (many diffs) |
70 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354424.2 | 71.1% | 70.7% | (many diffs) |
71 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354418.2 | 68.6% | 68.2% | (many diffs) |
72 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354419.2 | 68.6% | 68.2% | (many diffs) |
73 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003223.1 | 68.6% | 68.2% | (many diffs) |
74 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354426.2 | 62.4% | 62% | (many diffs) |
75 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354425.2 | 59.8% | 59.4% | (many diffs) |
76 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003230.1 | 59.8% | 59.4% | (many diffs) |
77 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354427.2 | 59.2% | 56.3% | (many diffs) |
78 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354428.2 | 58.8% | 55.8% | (many diffs) |
79 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452576.1 | 56.7% | 53.9% | (many diffs) |
80 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028559.2 | 47.8% | 42% | (many diffs) |
81 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XR_002959036.1 | 27.2% | (many diffs) | |
82 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148882.2 | 26.6% | (many diffs) | |
83 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148881.2 | 26.6% | (many diffs) | |
84 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148879.2 | 26.5% | (many diffs) | |
85 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148880.2 | 22.7% | (many diffs) | |
86 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | NM_026817.3 | 84.4% | 80.7% | (many diffs) |
87 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521326.3 | 84% | 80.3% | (many diffs) |
88 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521327.3 | 71.6% | 69.4% | (many diffs) |
89 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521329.3 | 53.1% | 48.9% | (many diffs) |
90 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_011245717.2 | 53.1% | 48.9% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 66
- ORF end:
- 753
- ORF length:
- 687
- Sequence:
-
1 gttcgttgca acaaattgat gagcaatgct tttttataat gccaaCTTTG TACAAAAAAG 61 TTGGCATGGC AGAAGACAAA ACCAAACCGA GTGAGTTGGA CCAAGGGAAG TATGATGCTG 121 ATGACAACGT GAAGATCATC TGCCTGGGAG ACAGCGCAGT GGGCAAATCC AAACTCATGG 181 AGAGATTTCT CATGGATGGC TTTCAGCCAC AGCAGCTGTC CACGTACGCC CTGACCCTGT 241 ACAAGCACAC AGCCACGGTA GATGGAAGGA CCATCCTTGT GGACTTTTGG GACACGGCAG 301 GCCAGGAGCG GTTCCAGAGC ATGCATGCCT CCTACTACCA CAAGGCCCAC GCCTGCATCA 361 TGGTGTTTGA TGTACAGAGG AAAGTCACCT ATAGGAACCT GAGCACCTGG TATACAGAGC 421 TTCGGGAGTT CAGGCCAGAG ATCCCATGCA TCGTGGTGGC CAATAAAATT GATGCAGACA 481 TAAACGTGAC CCAAAAAAGC TTCAATTTTG CCAAGAAGTT CTCCCTGCCC CTGTATTTCG 541 TCTCGGCTGC TGATGGTACC AATGTTGTGA AGCTCTTCAA TGATGCAATT CGATTAGCTG 601 TGTCTTACAA ACAGAACTCC CAGGACTTCA TGGATGAGAT TTTTCAGGAG CTCGAGAACT 661 TCAGCTTGGA GCAGGAAGAG GAGGACGTGC CAGACCAGGA ACAGAGCAGC AGCATCGAGA 721 CCCCATCAGA GGAGGCGGCC TCTCCCCACA GCTGCCCAAC TTTCTTGTAC AAAGTtggca 781 ttataagaaa gcattgctta tcaatttgtt gcaacgaac